Receptor Life Sciences

The series C venture capital round that Tessera Therapeutics announced on 19 April – totaling more than $300m, the company said – shows that investors continue to be willing to invest large sums in

Investors can't seem to get enough of biopharmaceutical companies developing drugs for non-alcoholic steatohepatitis (NASH), an indication with potentially millions of patients, no approved therapies

"The Pink Sheet" regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Jan. 16-2

Top Alliance: MannKind Licenses Technosphere to Receptor Stealthy start-up Receptor Life Sciences Inc. has licensed MannKind Corp. 's Technosphere dry powder delivery platform to develop inha